Aspira Women's Health (AWH) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, with voting available online or in person.
Proxy materials and the 2025 Annual Report are accessible online or by request before June 3, 2026.
Voting matters and shareholder proposals
Election of six director nominees is up for shareholder vote.
Advisory vote on executive compensation (say-on-pay) is included.
Amendment to the 2019 Stock Incentive Plan proposed for approval.
Ratification of BDO USA PC as independent auditor for fiscal year ending December 31, 2026.
Board of directors and corporate governance
Board recommends voting in favor of all director nominees and proposals.
Director nominees include Ellen Beausang, Jeffrey Cohen, M.D., John Fraser, Cynthia Hundorfean, Winfred Parnell, M.D., and Jane Pine Wood.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Aspira Women's Health
- Revenue fell 15% year-over-year, with improved net loss but ongoing liquidity concerns.AWH
Q2 2026 - Director ownership corrected; largest holder owns 14.1%; proxy votes remain valid.AWH
Proxy filing - AI-driven diagnostics improve detection and reduce surgeries in women's health.AWH
Investor presentation - Net income reached $676,000 despite a 14% revenue drop, but liquidity risks persist.AWH
Q1 2026 - Proxy covers director elections, executive pay, stock plan amendment, and auditor ratification.AWH
Proxy filing - Flat revenue, improved margins, and halved operating loss, but significant going concern risk remains.AWH
Q4 2025 - AI-driven diagnostics advance women's health, improving outcomes and financial performance.AWH
Investor presentation - $10M ARPA-H funding accelerates AI diagnostics for ovarian cancer and endometriosis.AWH
Investor Day 2024 - Q2 2024 saw 3% higher OvaSuite test volume, 48% OvaWatch growth, and new funding amid ongoing losses.AWH
Q2 2024